Clinical Trials Sponsored by Shenzhen Rhegen Biotechnology Co., Ltd.

Total 694 results

Wuhan Rhegen Biotechnology Co., Ltd.
Shenzhen Rhegen Biotechnology Co., Ltd.; Wuhan Recogen Biotechnology Co., Ltd.

Withdrawn

A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster

COVID-19 Pandemic
Shenzhen Shenxin Biotechnology Co., Ltd

Not yet recruiting

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

Herpes Zoster
Shenzhen Shenxin Biotechnology Co., Ltd

Not yet recruiting

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults

Respiratory Syncytial Virus Infections
Shenzhen Kangtai Biological Products Co., LTD
Beijing Minhai Biotechnology Co., Ltd

Not yet recruiting

A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)

COVID-19
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

Cervical Cancer | Papillomavirus Infections | CIN | Genital Wart | VIN

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
RemeGen Co., Ltd.

Not yet recruiting

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

High-risk Non-muscle Invasive Bladder Cancer

China
RemeGen Co., Ltd.

Recruiting

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Breast Cancer

China
RemeGen Co., Ltd.

Recruiting

A Study of RC118 Plus Toripalimab in Patients With Locally Advanced Unresectable or Metastatic Solid Tumors

Advanced Solid Tumor

China
RemeGen Co., Ltd.

Recruiting

A Study of RC148 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Solid Tumor

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Gastric Cancer

China
RemeGen Co., Ltd.

Recruiting

A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Urothelial Carcinoma | HER2-expressing

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Gastric Cancer | HER2 Overexpressing Gastric Carcinoma

China
RemeGen Co., Ltd.

Recruiting

RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial

Multiple Sclerosis, Relapsing-Remitting

China
RemeGen Co., Ltd.

Completed

Evaluation of RC28-E Injection in Diabetic Macular Edema

Diabetic Macular Edema

China
RemeGen Co., Ltd.

Terminated

A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

IgA Nephropathy

United States
RemeGen Co., Ltd.

Completed

Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

China
RemeGen Co., Ltd.

Active, not recruiting

A Study of RC98 in Subjects With Advanced Malignant Solid Tumors

Solid Tumors

China
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2

Gastric Cancer | HER2 Overexpressing Gastric Carcinoma

China
RemeGen Co., Ltd.

Completed

A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome

Primary Sjögren's Syndrome

China
RemeGen Co., Ltd.

Completed

Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors

Solid Tumors

China
RemeGen Co., Ltd.

Completed

Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

Systemic Lupus Erythematosus

China
RemeGen Co., Ltd.

Terminated

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

Moderate and Severe Rheumatoid Arthritis

China
RemeGen Co., Ltd.

Not yet recruiting

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Breast Cancer

China
RemeGen Co., Ltd.

Recruiting

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Breast Cancer

China
RemeGen Co., Ltd.

Recruiting

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Cervical Cancer

China
RemeGen Co., Ltd.

Recruiting

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

Solid Tumor

China
RemeGen Co., Ltd.

Recruiting

Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema

Diabetic Macular Edema

China
RemeGen Co., Ltd.

Recruiting

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

NSCLC

China
RemeGen Co., Ltd.

Recruiting

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

Advanced Solid Tumours

China
RemeGen Co., Ltd.

Not yet recruiting

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Non-small Cell Lung Cancer

China
RemeGen Co., Ltd.

Recruiting

Study of Telitacicept in Generalized Myasthenia Gravis

Myasthenia Gravis, Generalized

China
RemeGen Co., Ltd.

Recruiting

A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor

Digestive Cancer

China
RemeGen Co., Ltd.

Recruiting

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

Systemic Lupus Erythematosus

United States, Colombia, Bulgaria, Poland, Puerto Rico, Argentina, Australia, Chile, Hungary, Spain, Germany, Philippines
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Muscle Invasive Bladder Carcinoma

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Advanced Melanoma | Melanoma, Stage II | HER2-positive

China
RemeGen Co., Ltd.

Recruiting

A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors

Solid Tumor

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Breast Cancer

China
RemeGen Co., Ltd.

Active, not recruiting

A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer

Biliary Tract Cancer

China
RemeGen Co., Ltd.

Active, not recruiting

Evaluation of RC28-E Injection in Diabetic Retinopathy

Diabetic Retinopathy

China
RemeGen Co., Ltd.

Completed

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

Moderate and Severe RheumatoId Arthritis

China
RemeGen Co., Ltd.

Completed

A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours

Metastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid Tumor

Australia
RemeGen Co., Ltd.

Completed

Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

Systemic Lupus Erythematosus

China
RemeGen Co., Ltd.

Completed

Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration

Wet Age-Related Macular Degeneration

China
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors

Solid Tumors

China
RemeGen Co., Ltd.

Completed

A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

Advanced Cancer | Urothelial Carcinoma

China

3

Subscribe